hotspot -WSS

hotspot

author：leisure time 2025-10-01 02:15:35 - browse：4

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biden report: The neurospychology of memory and aging

hotspot

WSS

What we’ve learned from the Aduhelm mess

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Senators start work on Medicare physician payment reform

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Why some fertility treatments produce more boy babies

Ozempic cut risk of death in diabetes patients with chronic kidney disease

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medical records are filled with copy

What should King Charles tell the public about his cancer?

Sports medicine is finally prioritizing gender equality

Lawsuit challenges CMS nursing home minimum staffing rule

Tori Bowie and the unacceptable rates of Black maternal death

Why did Pfizer dish out millions for a Super Bowl ad?

New air purifier tech could be key to improving indoor air quality

For Medicare Advantage, Democrats want stronger protections around AI

After affirmative action ruling, medical educators look to 'holistic review'

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

Pharma’s losing bet in New Jersey

New research sheds light on how often breast cancer is overdiagnosed

Should insurance cover cosmetic surgery?

U.S. death rates show how politics are affecting public health

Biogen Alzheimer’s drug launch off to slow start

Stroke rates rising, especially in working

hotspot

focus

focus

hotspot